The separation into response and nonresponsive groups was even more effective with the Hammersmith discriminant. Of 52 patients with a negative Hammersmith discriminant, 6 (11 %) responded to treatment and of 61 with a positive discriminant, 24 (39 %) responded (X2 =9.07 P<0.005).
The survival of patients with positive discriminants of either type was significantly longer than that of those with negative discriminants (Fig 2) . At one year after the start of treatment approximately 70% of patients with a positive discriminant were alive and only 40% of those with a negative discriminant.
Conclusion: Response to endocrine treatment is related to the value of the discriminant function. The simple quick Hammersmith discriminant is at least as effective as the more complicated Guy's discriminant.
Discussion
The results of the first study indicate clearly that there is no advantage to be gained from early ablative surgery even though a third of the patients in the late ablation group died before the operation could be carried out. In these circumstances it seems advisable to start treatment invariably with simple methods and to reserve adrenalectomy or hypophysectomy until later.
The results of the discriminant study confirm the relationship between urinary steroid excretion and responsiveness to endocrine treatment and suggest that the essential estimations can be carried out simply, cheaply and quickly. The incidence of response in patients with a negative discriminant, however, remains too high for patients to be excluded from treatment for this reason alone. Used in combination with other factors such as the 'free interval' or menopausal status which also affect response, it seems likely that the method may be of greater value. The incidence of response in patients who have both a negative discriminant and a short free interval and those who are less than five years postmenopausal and have a negative discriminant seldom, if ever, respond and these patients might well be spared the unnecessary assault of major ablative surgery. Professor Harold Ellis (Surgical Unit, Westminster Hospital, London SWI)
Prevention of Recurrent Cancer of the Large Bowel
Each year some 15 000 patients die of large bowel cancer in England and Wales. Many of these have had previous so-called curative surgery yet subsequently develop either recurrent or metastatic disease. The fact that both these phenomena are so common means that our present knowledge about their prevention is pitifully small. Three mechanisms may be responsible for apparent local recurrence following resection: an overlooked second tumour or the development of a metachronous second primary; incomplete resection; and implantation of cells at the anastomosis, at any raw surface including the abdominal wound, and the peritoneal cavity at the time of surgery.
Disseminated secondaries probably represent the growth of microscopic foci already present at the initial resection, although it is possible that they result, in some instances, from tumour cells dislodged into the lymphatic or portal circulation during operation. What means are available to deal with these various possibilities ?
A second primary: Heald & Lockhart-Mummery (1972) stress the high incidence of a second tumour picked up within two years of the primary resection and which probably represents synchronous cancer missed at the initial operation. Routine sigmoidoscopy, barium enema studies and the more widespread use of the colonoscope should reduce this eventuality. Early pick up of metachronous cancers may be achieved by careful follow up. Heald & Lockhart-Mummery advocate six-monthly sigmoidoscopy and two-yearly double-contrast barium enema studies.
Incomplete resection: This is particularly likely to occur in anterior resections of the rectum. Unless being performed as a palliative measure, this should not be employed unless a comfortable 2 inches (5 cm) of rectum can be taken distal to the lower extremity of the tumour. Rectal sacrifice and a colostomy is preferable to a recurrence.
Prevention of implantations at the time ofsurgery:
Cancer cells shed at the time of surgery can undoubtedly seed at the anastomosis, on raw wound surfaces and over the peritoneum (Gilbertsen 1960 , Ryall 1907 , 1908 , Vink 1954 . The edges of the laparotomy wound should be meticulously protected by packs before the tumour is disturbed and the growth itself, especially if extending on to the overlying serosa, should be wrapped in a pack as soon as possible. Warren Cole (1952) introduced the simple technique of ligation of the bowel wall above and below the tumour in order to confine desquamating tumour cells. Smears taken outside these limiting ties are clear of malignant cells (Cole et al. 1954) . Irrigation with cytotoxic solutions reduces the risk of local implantation, especially in anterior resection of the rectum. Mercury perchloride remains a favourite (Golighet et al. 1951 , Naunton Morgan 1951 although Clorpactin, nitrogen mustard and others have their advocates. Hale (1969) , working in our laboratory, showed in the experimental animal that the effect was not mere mechanical lavage, since saline failed to prevent tumour implantation at colon anastomoses.
Preoperative radiotherapy might be expected to enhance survival and there is good experimental evidence that irradiation will inhibit the growth of tumour cells disseminated at surgery (Hoye & Smith 1961) . However, recent trials have failed to show convincing improvement compared with controls (Dwight et al. 1972 , Higgins et al. 1968 , Roswit et al. 1970 . Radiotherapy is of value as a palliative measure in advanced large bowel cancer (Whiteley et al. 1970) ; apart from this, its only preoperative indication appears to be in locally advanced cases at borderline resectability (Quan 1973 ).
Attempts to Prevent Dissemination ofMetastases
We are all too familiar with patients who undergo curative resection and who subsequently develop widespread disseminated deposits. Although most believe that in such cases these are already present microscopically at the time of the original operation, there is a body of opinion that, at least in some cases, handling of the tumour at surgery may be responsible for tumour dissemination, as was first shown experimentally by Tyzler (1913) . Turnbull (1970) strongly advocates his 'no-touch isolation technique', in which extreme care is taken to avoid handling the tumour mass before surgery; at operation the growth is not disturbed until the lymphovascular pedicles are tied and the colon divided at its elected sites of resection. Turnbull's published results are impressive, although his staging is rather different to that used in most other centres and his technique has not been submitted to clinical trial.
Another approach to the problem is the use of intraluminal chemotherapy at the time of operation to perfuse the lymphovenous drainage of the tumour. Rousselot & Cole (1962) first employed nitrogen mustard, but this proved ineffective. The same group (Grossi et al. 1972 ) now employ 5-fluorouracil, claim that their patients with lymph node involvement show higher survival in comparison with other published results, and they have instituted a multicentre trial. However, Higgins et al. (1971) have found no difference in survival between controls and patients receiving intravenous 5-fluorouracil commenced immediately postoperatively and continued in courses for two years in patients undergoing curative resection. There is, however, some improvement in survival in their palliative group.
It is interesting that the significance of freefloating malignant cells in peripheral blood is open to question. Griffiths et al. (1973) found tumour cells in the peripheral venous blood of 4% of over 200 patients with bowel cancer preoperatively, rising to 50% during operation. However, there was no relationship between their presence and prognosis. Indeed 56 % of patients with cancer cells in the peripheral blood at operation were alive and well five years later.
The dream for the future is the development of immunological methods to destroy microscopic residual foci of disease; perhaps a specific antibody linked with either a radioactive agent or cytotoxic drug (Morton 1973) . At present, with 50 % of our patients undergoing 'curative' resections dying of recurrent or metastatic disease before five years has passed, there is little room for complacency. There is urgent need for prophylaxis and effective therapy in this common and often lethal disease.
